Gerhard Held - Concepedia

Author

Gerhard Held

Also Known As

D Kraemer, Francesco D’Amore, G Held, G. HELD, G. Held, Gerald Wulf, Gerhard Held, Held, G., Held, Gerhar, Held, Gerhard

304

Publications

9.6K

Citations

H-Index

144

Concepts

All Affiliations

Saarland University University Hospital Ulm Heidelberg University Leipzig University Klinikum Oldenburg

About

Gerhard Held is an author at Saarland University specializing in medicine, engineering, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	36	2K
2	Engineering	17	17	1K
3	Health Sciences	8	8	479
4	Social Sciences	3	3	172
5	Public Health	1	1	14

Gerhard Held

112

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome Frank G. Rücker, Richard F. Schlenk, Lars Bullinger, Blood	2011	672
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML Sabine Käyser, Konstanze Döhner, Jürgen Krauter, Blood	2010	479
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation Richard F. Schlenk, Sabine Käyser, Lars Bullinger, Blood	2014	394
Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group Jan Krönke, Richard F. Schlenk, Kai‐Ole Jensen, Journal of Clinical Oncology	2011	388
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD Richard F. Schlenk, Daniela Weber, Walter Fiedler, Blood	2018	283
Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases Takao Morohoshi, Gerhard Held, Günter Klöppel Histopathology	1983	274
Structural and kinetic basis for heightened immunogenicity of T cell vaccines Ji‐Li Chen, Guillaume Stewart-Jones, Giovanna Bossi, The Journal of Experimental Medicine	2005	271
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features Verena I. Gaidzik, Veronica Teleanu, Elli Papaemmanuil, Leukemia Hematological MalignancyMedicineGeneticsAcute Myeloid LeukemiaHematology	2016	264
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial Viola Poeschel, Gerhard Held, Marita Ziepert, The Lancet	2019	244
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL Carsten Müller, Niels Murawski, Martin H. J. Wiesen, Blood	2012	233

Page 1